Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351(10):998–1012.

Article  CAS  PubMed  Google Scholar 

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84.

Article  CAS  PubMed  Google Scholar 

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.

Article  CAS  PubMed  Google Scholar 

• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. New Engl J Med. 2015;372(26):2521–32 (Demonstrated improved clinical outcomes as well as improved tolerability with anti-PD1 therapy when compared to ipilimumab).

Article  CAS  PubMed  Google Scholar 

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127–37 (Describes the 6.5 year outcomes of CheckMate-067, with median OS 72 months in the ipilimumab/nivolumab arm. This potential for durable clinical benefit and off-treatment survival was previously unprecedented in solid tumor oncology and has transformed melanoma treatment algorithms.).

Article  CAS  PubMed  Google Scholar 

•• Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. New Engl J Med. 2022;386(1):24–34 (RELATIVITY-047 demonstrated clinical benefit with the PD-1-LAG-3 antibody combination nivolumab/relatlimab compared to nivolumab and established nivolumab/relatlimab as a standard of care front-line ICI regimen for metastatic melanoma.).

Article  CAS  PubMed  Google Scholar 

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–88.

Article  PubMed  Google Scholar 

Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, et al. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. J Clin Oncol. 2020;38(33):3937–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, et al. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. J Clin Oncol. 2023;41(24):3998–4003.

Article  CAS  PubMed  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34.

Article  PubMed  PubMed Central  Google Scholar 

Regan MM, Werner L, Rao S, Gupte-Singh K, Hodi FS, Kirkwood JM, et al. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2019;37(35):3350–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, et al. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evid. 2023;2(4):EVIDoa2200239.

Article  PubMed  Google Scholar 

Hamid O, Lewis KD, Weise AM, et al. Significant durable response with fianlimab (anti–LAG-3) and cemiplimab (anti–PD-1) in advanced melanoma: post adjuvant PD-1 analysis. J Clin Oncol. 2023;41(suppl_16):9501.

Lebbe C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, et al. Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: three-year results of CheckMate 511. J Clin Oncol 39 15 9516 2021.

Article  Google Scholar 

Postow MA, Goldman DA, Shoushtari AN, Betof Warner A, Callahan MK, Momtaz P, et al. Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). J Clin Oncol. 2022;40(10):1059–67.

Article  CAS  PubMed  Google Scholar 

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.

Article  CAS  PubMed  Google Scholar 

•• Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186–97 (Demonstrated improved 2 year OS for patients who initiated therapy with ipilimumab/nivolumab compared to dabrafenib/trametinib, highlighting that most patients with metastatic melanoma should receive immunotherapy as first line treatment.).

Article  CAS  PubMed  Google Scholar 

Ascierto PA, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, et al. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nat Commun. 2024;15(1):146.

Article  PubMed  PubMed Central  Google Scholar 

Atkins MBLSJ, Chmielowski B, Tarhini A, Cohen GI, Gibney GT, Truong TG, Diwakar D, O’Rourke MA, Curti BD, Brell JM, Kendra KL, Ikeguchi A, Guild S, Jain SS, Wellstein A, Wolchok JD, Ribas A, Kirkwood JM. DREAMseq (EA6134): A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM): Final 2-year OS data and biomarkers. Pigment Cell Melanoma Res. 2024;37(1):90–226.

Google Scholar 

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9.

Article  PubMed  Google Scholar 

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626–36.

Article  CAS  PubMed  Google Scholar 

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–15.

Article  CAS  PubMed  Google Scholar 

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315–27.

Article  CAS  PubMed  Google Scholar 

• Haydon A, Schadendorf D, Dummer R, Flaherty K, Robert C, Fernandez AA, et al. 602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco)+ binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma. Annals of Oncology. 2023;34:S1707–8 (The 7-year follow up of COLUMBUS demonstrated potential for long-term benefit with encorafenib/binimetinib in a subset of patients, with 7 year PFS approximately 20%.).

Article  Google Scholar 

Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.

Article  PubMed  Google Scholar 

Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015;7(279):279ra41.

Article  PubMed  PubMed Central  Google Scholar 

Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835–44.

Article  CAS  PubMed  Google Scholar 

Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, et al. KEYNOTE-022 international team. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer. 2020;8(2):e001806.

Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, et al. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. J Clin Oncol. 2022;40(13):1428–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–21.

Article  PubMed  PubMed Central  Google Scholar 

Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, et al. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. J Clin Oncol. 2019;37(1):52–60.

Article  CAS  PubMed  Google Scholar 

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018;379(8):722–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021;22(12):1692–704 (The long-term outcomes of CheckMate 204 demonstrate potential for durable response and survival in patients who receive ipilimumab/nivolumab for untreated, asymptomatic melanoma brain metastases. These results have established up-front ipilimumab/nivolumab as a standard of care for highly selected patients with untreated melanoma brain metastases.).

Article  CAS  PubMed  PubMed Central  Google Sc